Healx, a Cambridge, UK-based healthcare company that seeks new uses for existing drugs in the fight against rare diseases, raised £1.5m in Series A funding.
The round was led by global technology investor Amadeus Capital Partners with participation from healthcare entrepreneur Jonathan Milner. Board members include bio-tech entrepreneur, Darrin Disley, and drug development leader, David Brown, co-inventor of Viagra.
The company intends to use the funds to expand its echnology platform and accelerate its drug review process to find treatments to additional illnesses.
Led by Tim Guilliams, Chief Executive, Healx uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis to identify novel drug applications for rare diseases that afflict some 350 million people worldwide. Their model engages directly with patient advocacy groups, allowing them to lead the way in personalized healthcare for rare diseases.
The company has won contracts from major medical foundations in the US and Europe to find drug candidates to treat conditions including childhood diseases, Barth syndrome and Fragile-X.